Binding Molecule Having Influenza A Virus-Neutralizing Activity Produced from Human B Cell

Patent metadata

Field	Value
Publication number	US-2017037113-A1
Application number	US-201615259823-A
Country	US
Kind code	A1
Filing date	Sep 8, 2016
Priority date	Sep 30, 2011
Publication date	Feb 9, 2017
Grant date	—

Abstract

The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.

First claim

1 - 45 . (canceled)

46 . A binding molecule which comprises:
(a) a binding molecule composed of a light chain comprising, as determined according to the Kabat method, a CDR1 region set forth in SEQ ID NO: 1, a CDR2 region set forth in SEQ ID NO: 2, and a CDR3 region set forth in SEQ ID NO: 3, and a heavy chain comprising, as determined according to the Kabat method, a CDR1 region set forth in SEQ ID NO: 4, a CDR2 region set forth in SEQ ID NO: 5, and a CDR3 region set forth in SEQ ID NO: 6; (b) a binding molecule composed of a light chain comprising, as determined according to the Kabat method, a CDR1 region set forth in SEQ ID NO: 7, a CDR2 region set forth in SEQ ID NO: 8, and a CDR3 region set forth in SEQ ID NO: 9, and a heavy chain comprising, as determined according to the Kabat method, a CDR1 region set forth in SEQ ID NO: 10, a CDR2 region set forth in SEQ ID NO: 11, and a CDR3 region set forth in SEQ ID NO: 12; (c) a binding molecule composed of a light chain comprising, as determined according to the Kabat method, a CDR1 region set forth in SEQ ID NO: 13, a CDR2 region set forth in SEQ ID NO: 8, and a CDR3 region set forth in SEQ ID NO: 9, and a heavy chain comprising, as determined according to the Kabat method, a CDR1 region set forth in SEQ ID NO: 10, a CDR2 region set forth in SEQ ID NO: 14, and a CDR3 region set forth in SEQ ID NO: 6; or (d) a binding molecule composed of a light chain comprising, as determined according to the Kabat method, a CDR1 region set forth in SEQ ID NO: 15, a CDR2 region set forth in SEQ ID NO: 16, and a CDR3 region set forth in SEQ ID NO: 9, and a heavy chain comprising, as determined according to the Kabat method, a CDR1 region set forth in SEQ ID NO: 10, a CDR2 region set forth in SEQ ID NO: 17, and a CDR3 region set forth in SEQ ID NO: 12, wherein the binding molecule is produced by a non-human mammalian cell culture.

47 . The binding molecule of claim 46 , wherein the binding molecule is composed of a light chain comprising a polypeptide sequence set forth in SEQ ID NO: 37, and a heavy chain comprising a polypeptide sequence set forth in SEQ ID NO: 38.

48 . The binding molecule of claim 46 , wherein the binding molecule is composed of a light chain comprising a polypeptide sequence set forth in SEQ ID NO: 39, and a heavy chain comprising a polypeptide sequence set forth in SEQ ID NO: 40.

49 . The binding molecule of claim 46 , wherein the binding molecule is composed of a light chain comprising a polypeptide sequence set forth in SEQ ID NO: 41, and a heavy chain comprising a polypeptide sequence set forth in SEQ ID NO: 42.

50 . The binding molecule of claim 46 , wherein the binding molecule is composed of a light chain comprising a polypeptide sequence set forth in SEQ ID NO: 43, and a heavy chain comprising a polypeptide sequence set forth in SEQ ID NO: 44.

51 . The binding molecule of claim 46 , wherein the binding molecule is an antibody.

52 . The binding molecule of claim 51 , wherein the antibody is a Fab fragment, a Fv fragment, a diabody, a chimeric antibody, a humanized antibody or a human antibody.

53 . The binding molecule of claim 46 , wherein the non-human mammalian cell culture is CHO cells, COS cells or BHK cells.

54 . A composition comprising a binding molecule having neutralizing activity against influenza A virus according to claim 46 .

55 . A composition for preventing and treating a disease caused by influenza A virus, the composition comprising a binding molecule having neutralizing activity against influenza A virus according to claim 46 .

56 . The composition of claim 55 , wherein the tag is any one selected from the group consisting of enzymes, luciferases, radioactive isotopes, and toxin.

57 . A kit for diagnosis of influenza A virus, comprising:
i) a binding molecule having neutralizing activity against influenza A virus according to any one of claim 46 ; and ii) a container.

58 . The kit of claim 57 , wherein the influenza A virus is selected from the group consisting of H1, H3, H5, H7 and H9 subtypes.

Assignees

• Celltrion Inc

Inventors

• Chang Shin Jae
• Kwon Ki Sung
• Yi Kye Sook
• Lee Hyun Joo
• Jeon Jae Won
• Jun Hwang Keun
• Chang Min Seok

Classifications

• A61P31/16

  for influenza or rhinoviruses · CPC title

• C07K16/108 Primary

  Orthomyxoviridae (F), e.g. influenza virus · CPC title

• G01N2500/00

  Screening for compounds of potential therapeutic value · CPC title

• C07K2317/51

  Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title

• A61K2039/505

  comprising antibodies · CPC title